For patients with rheumatic disease, general treatment guidelines for managing cardiovascular risk are suboptimal, says Katherine Liao, MD. A patient’s level of disease activity and inflammation affect their risk…
Search results for: cardiovascular disease
No Longer as Vexing: The Role of Somatic Mutations in Rheumatic Diseases
At this ACR Convergence 2025 session, two experts discussed VEXAS & the role that genetic sequencing should play in the practice of a rheumatologist.
Does High-Intensity Interval Training Lower Inflammatory Disease Activity?
Experts discuss high-intensity interval training as an underused “disease-modifying drug” for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
Study: Reducing Cardiovascular Risks Helps Lupus Patients
Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Sleep Disorders & Rheumatic Disease
ACR Convergence 2024—With poor sleep a major complaint among patients with rheumatologic diseases, physicians should hone their understanding of how the body regulates sleep and how this system can be disrupted, and tailor their management plans to help patients with these issues, panelists said in a session at ACR Convergence. For some patients, their struggles…
The Great Pediatric Debate 2024: Cessation or Continuation of Biologics in sJIA Lung Disease?
Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…
Cardiovascular & Cancer Risk Factors with JAK Inhibitors
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
Consensus Guidelines on Diagnostic Approach to Giant Cell Arteritis Arrive from Society for Cardiovascular Pathology
At the end of 2023, the Society for Cardiovascular Pathology (SCVP) published consensus guidelines on the diagnostic approach to temporal artery biopsy.1 Through this publication, SCVP hopes to bring more uniformity to the processing, interpretation and reporting of these specimens, taking into consideration the most up-to-date literature available. These guidelines have obvious impact on clinical…
Lifestyle Medicine Interventions Can Benefit Patients with Rheumatic Disease
Lifestyle medicine interventions, such as dietary changes, movement and mindfulness, in combination with conventional treatment, may help alleviate symptoms of rheumatic disease, according to panelists at ACR Convergence 2023.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 66
- Next Page »